UK-based Ergomed, dedicated to the provision of services for developing new drugs, has appointed Andrew Mackie as chief business officer and to its board as executive director.
Mackie brings over 25 years’ industry experience in pre-clinical research, clinical development and business development, having held a number of senior R&D roles in pharmaceutical (Lilly, Novartis, Sanofi), service (MDS) and biotech companies (Antisoma). He joins Ergomed from Eli Lilly where he was working for the business development team. Prior to this, he was head of Life Sciences at IP Group.
After ten years in R&D, Mackie joined the UK biotech sector in 1997 at Antisoma, the oncology specialist. He establish the clinical development department and transitioned new molecules into development and later managed Antisoma’s strategic alliance with F Hoffman-La Roche and in-licensed new drug leads through partnerships and acquisitions.
Rolf Stahel, chairman of Ergomed, commented: “I am very pleased to welcome Andrew to the Ergomed board. His expertise and experience will be invaluable as we continue to grow our services and co-development business and expand into new related areas.